GlyCaBiota Doctoral Training Network on Glycan–Cancer–Microbiota Interactions for Therapeutic and Diagnostic Innovation in Colorectal cancer
- Coordinator
- Universidade Nova De Lisboa, Portugal
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €4.7m
- Total cost
- —
- Partners
- 20 organisations in 9 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101312796
What the project is doing
In the project's own words, from its summary on CORDIS.
Colorectal cancer (CRC) remains a major global health challenge, and increasing evidence shows that gut microbiota plays a decisive role in tumour progression and immune escape. Yet, the molecular rules governing communication between tumour cells, microbes and the immune system remain unknown. GlyCaBiota DN addresses this critical gap by focusing on how tumour and microbial glycans and proteins that recognize them shape CRC biology.
Our innovative programme places glycan-mediated interactions at the core of the tumour–microbiota–immune axis, enabling the rational development of next-generation diagnostic and therapeutic strategies. By combining structural, cellular and computational approaches, GlyCaBiota will decode the molecular mechanisms driving microbial colonisation, immune modulation and CRC progression. Our consortium brings together leading experts in glycoscience, microbiology, cancer biology and immunology, structural biology, bioinformatics and translational research.
With nine academic and five industrial partners, one oncology center and an international network, GlyCaBiota provides complementary expertise, unique tools and clinical connections to train 15 doctoral candidates (DCs). The combination of excellent interdisciplinary science, industry know-how and clinical perspective covers the entire pipeline from fundamental discoveries to innovative solutions. DCs will gain cutting-edge scientific and transferable skills, positioning them for impactful careers across academia, industry and healthcare.
GlyCaBiota will create a critical mass of researchers capable of integrating glycoscience and microbiome research to tackle key challenges in CRC. By deciphering glycan-mediated interactions, GlyCaBiota will expand fundamental knowledge and strengthen European innovation capacity, enabling future development of precision diagnostics and therapeutic strategies for CRC.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Nova De Lisboa | Lisboa | Portugal | Coordinator |
| Canadian Glycomics Network | Edmonton | Canada | Associatedpartner |
| Sib Swiss Institute of Bioinformatics | Genf | Switzerland | Participant |
| Glycodisplay Aps | Kobehavn | Denmark | Associatedpartner |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Adaptam Therapeutics SL | San Sebastian | Spain | Associatedpartner |
| Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune | Derio Vizcaya | Spain | Participant |
| Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea | Leioa | Spain | Associatedpartner |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Universite Grenoble Alpes | Grenoble | France | Associatedpartner |
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| GlycoTherapeutics B.V. | Nijmegen | Netherlands | Participant |
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Associatedpartner |
| Instituto Portugues De Oncologia Do Porto Francisco Gentil, Epe | Porto | Portugal | Associatedpartner |
| Nzytech Lda | Lisboa | Portugal | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Participant |
| Ludger Limited | Abingdon | United Kingdom | Participant |
| Quadram Institute Bioscience | Norwich | United Kingdom | Participant |
| University of East Anglia | Norwich | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI